Division of Gastroenterology, MGH Alcohol Liver Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114, USA.
Department of Medicine, Gastrointestinal Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114, USA.
Clin Exp Med. 2022 Feb;22(1):103-110. doi: 10.1007/s10238-021-00736-6. Epub 2021 Jul 1.
While alcohol use has been shown to increase serum HDL, advanced liver disease associates with decreased serum HDL. The combined influence of alcohol consumption and liver fibrosis is poorly defined. In this study, we sought to investigate the competing effects of alcohol use and hepatic fibrosis on serum HDL and to determine if the presence of advanced hepatic fibrosis ablates the reported effect of alcohol consumption on serum HDL. We performed a cross-sectional, exploratory analysis examining the interaction between alcohol use and advanced hepatic fibrosis on serum HDL levels in 10,528 patients from the Partners Biobank. Hepatic fibrosis was assessed using the FIB-4 index. We excluded patients with baseline characteristics that affect serum HDL, independent of alcohol use or the presence or advanced hepatic fibrosis. We observed an incremental correlation between increasing HDL levels and amount of alcohol consumed (P < 0.0001), plateauing in those individuals who drink 1-2 drinks per day, Contrastingly, we found a negative association between the presence of advanced hepatic fibrosis and lower HDL levels, independent of alcohol use (beta coefficient: -0.011075, SEM0.003091, P value: 0.0001). Finally, when comparing subjects with advanced hepatic fibrosis who do not use alcohol to those who do, we observed that alcohol use is associated with increased HDL levels (54.58 mg/dL vs 67.26 mg/dL, p = 0.0009). This HDL-elevating effect of alcohol was more pronounced than that seen in patients without evidence of advanced hepatic fibrosis (60.88 mg/dL vs 67.93 mg/dL, p < 0.0001). Our data suggest that the presence of advanced hepatic fibrosis does not blunt the HDL-elevating effect of alcohol use.
虽然饮酒已被证明会增加血清高密度脂蛋白(HDL),但晚期肝病会导致血清 HDL 降低。酒精摄入和肝纤维化的综合影响尚未明确。在这项研究中,我们旨在研究酒精摄入和肝纤维化对血清 HDL 的相互竞争的影响,并确定晚期肝纤维化是否会消除酒精摄入对血清 HDL 的报道影响。我们对来自合作伙伴生物库的 10528 名患者进行了一项横断面、探索性分析,以研究酒精摄入和晚期肝纤维化对血清 HDL 水平的相互作用。肝纤维化使用 FIB-4 指数评估。我们排除了那些受酒精摄入或存在或晚期肝纤维化以外的因素影响血清 HDL 的基线特征的患者。我们观察到,随着 HDL 水平的升高,饮酒量呈递增相关性(P < 0.0001),在每天饮酒 1-2 杯的人群中达到平台期。相反,我们发现,无论是否饮酒,晚期肝纤维化的存在与 HDL 水平降低呈负相关(β系数:-0.011075,SEM0.003091,P 值:0.0001)。最后,当比较不饮酒和饮酒的晚期肝纤维化患者时,我们发现饮酒与 HDL 水平升高相关(54.58mg/dL 与 67.26mg/dL,p=0.0009)。这种酒精升高 HDL 的作用比在没有晚期肝纤维化证据的患者中更为明显(60.88mg/dL 与 67.93mg/dL,p < 0.0001)。我们的数据表明,晚期肝纤维化的存在不会削弱酒精摄入对 HDL 的升高作用。